Literature DB >> 10704546

Frequency doubling technology perimetry for detection of glaucomatous visual field loss.

K E Cello1, J M Nelson-Quigg, C A Johnson.   

Abstract

PURPOSE: To evaluate the ability of frequency doubling technology perimetry to detect early, moderate, and advanced glaucomatous visual field loss.
METHODS: In a prospective study, frequency doubling technology perimetry (C-20 full threshold) was performed in the right eye of 254 normal control subjects and 230 patients with early (n = 85), moderate (n = 114), or advanced (n = 31) glaucomatous visual field loss. Previous Humphrey Field Analyzer test results were used to classify glaucomatous visual field loss as early (mean deviation no worse than -6 dB), moderate (mean deviation between -6 and -12 dB) or advanced (mean deviation between -12 and -22 dB).
RESULTS: Receiver operating characteristic curves showed 100% sensitivity and specificity (area under the curve, 1.0) for detecting advanced glaucomatous visual field loss, approximately 96% sensitivity and 96% specificity (area under the curve, 0.9751) for detecting moderate glaucomatous visual field loss, and approximately 85% sensitivity and 90% specificity (area under the curve, 0.9261) for early glaucomatous visual field loss.
CONCLUSIONS: Frequency doubling technology perimetry demonstrates high sensitivity and specificity for detection of early, moderate, and advanced glaucomatous visual field loss.

Entities:  

Mesh:

Year:  2000        PMID: 10704546     DOI: 10.1016/s0002-9394(99)00414-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  51 in total

1.  Clinical comparison of frequency doubling technology perimetry and Humphrey perimetry.

Authors:  R Casson; B James; A Rubinstein; H Ali
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

2.  Correlation between frequency doubling technology perimetry and temporal frequency characteristics in early glaucoma.

Authors:  Joseph Jy-Haw Yu; Motohiro Kiyosawa; Nobuyuki Nemoto; Keiko Momose; Hiroshi Mori; Manabu Mochizuki
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

3.  [Importance of flicker contrast tests in functional glaucoma diagnostics].

Authors:  K Göbel; C M Poloschek; C Erb; M Bach
Journal:  Ophthalmologe       Date:  2012-04       Impact factor: 1.059

4.  The distribution of visual field defects per quadrant in standard automated perimetry as compared to frequency doubling technology perimetry.

Authors:  Wadih M Zein; Ziad F Bashshur; Rola F Jaafar; Baha' N Noureddin
Journal:  Int Ophthalmol       Date:  2010-10-06       Impact factor: 2.031

5.  Probing glaucoma visual damage by rarebit perimetry.

Authors:  P Brusini; M L Salvetat; L Parisi; M Zeppieri
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

6.  Performance of the 24-2-5 frequency doubling technology screening test: a prospective case study.

Authors:  P G D Spry; H M Hussin; J M Sparrow
Journal:  Br J Ophthalmol       Date:  2007-03-27       Impact factor: 4.638

7.  Interpretation of the Humphrey Matrix 24-2 test in the diagnosis of preperimetric glaucoma.

Authors:  Jin A Choi; Na Young Lee; Chan Kee Park
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

Review 8.  [Functional glaucoma diagnosis].

Authors:  C Erb; K Göbel
Journal:  Ophthalmologe       Date:  2009-04       Impact factor: 1.059

9.  Evaluation of corpus geniculatum laterale and vitreous fluid by magnetic resonance spectroscopy in patients with glaucoma; a preliminary study.

Authors:  S Doganay; C Cankaya; A Alkan
Journal:  Eye (Lond)       Date:  2012-05-25       Impact factor: 3.775

10.  Predicting progression of glaucoma from rates of frequency doubling technology perimetry change.

Authors:  Daniel Meira-Freitas; Andrew J Tatham; Renato Lisboa; Tung-Mei Kuang; Linda M Zangwill; Robert N Weinreb; Christopher A Girkin; Jeffrey M Liebmann; Felipe A Medeiros
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.